Bioequivalence testing of generic drugs
 |
1) What is bioavailability & bioequivalence — short and sharp
- Bioavailability (BA): fraction and rate at which the active moiety reaches systemic circulation and is available at the site of action (in practice: measured in plasma).
- Bioequivalence (BE): two products are BE if they show no significant difference in the rate and extent of absorption — usually the generic (test) vs the reference/canadian reference product (CRP). Purpose: ensure therapeutic equivalence so patients can be switched safely.
2) Primary pharmacokinetic parameters used
- AUC₀–t (or AUC₀–∞) — area under plasma concentration–time curve → extent of absorption.
- Cmax — peak plasma concentration → rate (and partly extent).
- Tmax — time to Cmax (descriptive; not used for BE decision usually).
- For some drugs: partial AUCs, Cτ (trough), or AUC over a dosing interval may be used (e.g., modified-release products).
3) Standard statistical BE criterion (what to memorise)
- Average Bioequivalence (ABE): two-sided 90% confidence interval (CI) for the ratio (Test/Reference) of geometric means of AUC and Cmax must fall within 80.00% – 125.00%. This is the canonical rule for most small-molecule generics. (PEBC will expect you to state the 80–125% rule and 90% CI).
4) Typical BE study design
- Healthy volunteers are usually used (unless safety or sensitivity reasons require patients).
- Designs:
- Two-period, two-sequence crossover (most common) — each subject receives test and reference with washout period.
- Parallel design — used for long half-life drugs or when carryover unacceptable.
- Replicate designs (e.g., 2×4, 3×3) — used to estimate within-subject variability and for Reference-Scaled ABE (HVDs).
- Fasting vs fed: For immediate-release oral solids, FDA/Health Canada usually require fasting BE study; a fed study may be required if the product label instructs to take with food or food affects absorption significantly.
5) Analytical & operational essentials
- Assay: validated, selective, sensitive bioanalytical method (usually LC-MS/MS) to quantify parent drug (sometimes metabolite).
- Sampling: enough samples to capture absorption and elimination phases; plan for PK calculations and partial AUC if needed.
- Sample size: calculated from expected within-subject CV, desired power (usually ≥80–90%), and regulatory criteria.
- Randomisation, blinding (where possible), protocol compliance and washout must be appropriate.
6) Special statistical issues — Highly Variable Drugs & Narrow Therapeutic Index
- Highly Variable Drugs (HVDs): within-subject CV ≥ ~30% for a PK metric (often Cmax). For HVDs, Reference-Scaled Average Bioequivalence (RSABE) (reference-scaled ABE) allows widened limits based on variability (statistical scaling), but strict rules apply. Replicate designs are usually required.
- Narrow Therapeutic Index (NTI) drugs: regulators may require narrower BE limits (e.g., 90–111% or other country-specific tighter margins) and sometimes clinical safety data (examples: warfarin, levothyroxine — country specifics may vary). Mentioning NTI and the need for caution earns marks.
7) When in vitro tests can replace in vivo studies
- Biowaivers: For certain immediate-release solid oral dosage forms, if the generic meets ICH BCS (Biopharmaceutics Classification System) criteria (e.g., BCS Class I — high solubility, high permeability — or some Class III with additional requirements) and in vitro dissolution similarity, regulators may grant a biowaiver (no in vivo BE study needed). State the concept and BCS tie-ins.
8) Reference product selection and foreign comparators
- Use the Canadian Reference Product (CRP) where available. Health Canada allows use of an acceptable foreign-sourced reference in some cases, but sponsors must justify and meet bridging requirements (comparative testing) — important for ANDS submissions. Always mention Canadian guidance on foreign comparators.
9) Key regulatory documents & country-specific notes (brief)
- Health Canada: Guidance on bioavailability & bioequivalence; conduct and analysis of comparative BA studies. PEBC = Canada — reference Health Canada documents in answers.
- FDA: Bioequivalence and statistical guidance documents (useful for methods, RSABE, study design).
- WHO: Guidelines on evaluation of biosimilars / similar biotherapeutic products — important for biologics discussion.
10) Special considerations for biopharmaceuticals (biologics & biosimilars) — the big differences from small-molecule generics
Short point first: Biologics are large, structurally complex, produced in living systems — so “generic” ≠ “biosimilar”. Biosimilars require a comparability package (extensive analytical comparability + targeted nonclinical/clinical work) rather than only classical PK BE.
A. Why biologics are different
- Produced in living cells → microheterogeneity (glycosylation patterns, folding, PTMs).
- Product = molecule plus its quality attributes (aggregates, charge variants, glycoforms, host-cell proteins). Small differences can impact efficacy, safety, immunogenicity.
B. Regulatory approach for biosimilars
- Stepwise comparability (totality of evidence):
- Extensive physicochemical & biological characterisation using orthogonal advanced analytics (mass spectrometry, glycan mapping, peptide mapping, bioassays).
- Nonclinical in vitro / in vivo comparability as needed.
- Clinical PK/PD comparability (pharmacokinetics and, where appropriate, pharmacodynamics markers).
- At least one clinical efficacy/safety/immunogenicity study may be required depending on residual uncertainty; some regulators are moving to reduce clinical requirements when analytical similarity is very strong. (Health Canada draft moves reflect this trend.)
C. Key endpoints & assays for biologics
- PK endpoints: AUC and Cmax of the biological (or surrogate).
- PD endpoints: sometimes used if a robust PD marker exists (e.g., absolute neutrophil count for filgrastim).
- Immunogenicity: anti-drug antibodies (ADA) — must be assessed (binding and neutralising) and compared between products. ADA can alter PK, efficacy and safety.
- Functional assays: bioassays showing activity (e.g., cell proliferation, receptor binding).
D. Interchangeability & extrapolation of indications
- Interchangeability (automatic substitution at pharmacy) rules differ by jurisdiction; in Canada, provincial formularies and Health Canada guidance play roles — interchangeability requires confidence in similarity including immunogenicity.
- Extrapolation: regulators may extrapolate indications from one clinical setting to others if the mechanism of action, receptor, and PK/PD support it — must be justified scientifically.
E. Manufacturing & quality control issues
- Process changes / comparability: manufacturers must demonstrate comparability if manufacturing changes occur (critical for biologics).
- Lot-to-lot consistency, control of impurities and aggregates, and stability are heavily scrutinised.
F. Recent regulatory trends (Canada & global)
- Health Canada (2025 draft) is moving toward streamlined biosimilar review with greater emphasis on analytical quality and less on routine large Phase III trials when similarity is clear — but immunogenicity and targeted clinical data remain important. Always flag that guidance is evolving and cite the draft.
11) PEBC-ready high-yield checklist (memorise these lines)
- Define BA and BE.
- State 80–125% with 90% CI for AUC and Cmax (ABE).
- Mention study design: two-period crossover in healthy volunteers; replicate designs for HVD; parallel for long t½.
- Note BCS biowaiver concept for immediate-release solid oral dosage forms (BCS I/III conditional).
- For HVD → RSABE and replicate designs; for NTI → tighter limits may apply.
- For biologics → totality of evidence: analytical comparability → targeted nonclinical → PK/PD → immunogenicity/clinical. Extrapolation allowed with justification.
12) Example short answer (PEBC style)
Q: “Describe bioequivalence requirements for a generic immediate-release oral tablet and list special issues for biologic products.”
A model answer (concise points to write in exam):
- Define BA and BE. State purpose (therapeutic equivalence).
- BE demonstrated by PK endpoints (AUC, Cmax); 90% CI of geometric mean Test/Reference between 80–125% for AUC and Cmax. Mention partial AUC/Tmax as supportive if required.
- Typical design: healthy volunteers, randomized two-period crossover, adequate washout; fed study if food affects absorption. Assay must be validated.
- For HVDs use replicate designs and reference-scaled ABE; for NTI consider narrower limits. BCS biowaiver possible for certain IR solids.
- Biologics: product complexity demands analytical comparability, functional assays, immunogenicity assessment, PK/PD studies, and selective clinical data. Extrapolation of indications possible with robust justification; interchangeability depends on jurisdiction. Conclude with reference to Health Canada/WHO/FDA guidance.
13) exam tips & traps to avoid
- Don’t mix up “generic = chemically identical” (wrong) vs “generic = pharmaceutically equivalent & bioequivalent”. For small molecules, generics can be qualitatively same API and bioequivalent; for biologics, biosimilar is not identical.
- Always state CI and range (80–125%). If asked about NTI or HVD, mention narrower ranges or RSABE respectively.
- If asked regulatory specifics for Canada, mention Health Canada guidance and Canadian Reference Product / foreign comparator guidance.
14) Further reading (authoritative sources — bookmark these)
- Health Canada — Bioavailability and bioequivalence & Conduct and analysis of comparative bioavailability studies.
- FDA — Bioequivalence Studies for Generic Drug Development and Statistical Approaches to Establishing Bioequivalence.
- WHO — Guidelines on evaluation of similar biotherapeutic products (biosimilars).
- Health Canada (2025 draft) — Draft guidance on biosimilars (monitor for finalisation if you refer to policy changes).